(NASDAQ: VERA) Vera Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Vera Therapeutics's revenue in 2024 is $0.On average, 5 Wall Street analysts forecast VERA's revenue for 2026 to be $1,114,306,321, with the lowest VERA revenue forecast at $427,448,428, and the highest VERA revenue forecast at $1,783,303,950. On average, 4 Wall Street analysts forecast VERA's revenue for 2027 to be $6,310,717,901, with the lowest VERA revenue forecast at $4,425,860,917, and the highest VERA revenue forecast at $8,816,872,536.
In 2028, VERA is forecast to generate $17,900,396,657 in revenue, with the lowest revenue forecast at $11,702,285,552 and the highest revenue forecast at $25,496,618,059.